Business
Dyadic Reports Third Quarter 2022 Financial Results and Highlights Recent Company Developments
Received regulatory approval from South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 clinical trial to demonstrate clinical
About this update from Dyadic International, Inc.
[{"type":"text","content":"Received regulatory approval from South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 clinical trial to demonstrate clinical safety and antibody response in humans for DYAI-100 COVID-19 recombinant protein RBD booster vaccine candidatePresented safety, efficacy, and productivity data at World Vaccine Congress EuropeNew and expanded collaborations with top animal health companies to develop vaccines and treatments for companion and livestock animal diseasesInitiated multiple product candidates to support the newly launched Dapibus™ platform, a fungal-based microbial platform for use in non-pharmaceutical applications such as food, nutrition, health, and wellnessCash and investment grade securities of $14.2 million as of September 30, 2022Financial results and business update conference call scheduled for 5:00 pm EST today JUPITER, Fla., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet clinical needs for effective and affordable biopharmaceutical products for human and animal health, today announced its financial results for the third quarter of 2022, and highlighted recent company developments. “The approval of our first-in-human clinical trial application with the South African Health Products Regulatory Authority (SAHPRA) to initiate a Phase 1 clinical trial is a significant milestone for Dyadic which further supports the C1-cell protein production platform as a potentially transformational technology for use in developing and manufacturing biopharmaceuticals,” said Mark Emalfarb, President and Chief Executive Officer of Dyadic. “In addition to establishing a safety record with regulatory agencies for proteins produced from C1-cells we continually strive to improve productivity and quality and, in some cases efficacy, of those proteins. These efforts led to several scientific breakthroughs this quarter, including increased protein expression levels through the application of our new genetic approaches in engineering C1- cells. “In our Alternative Proteins vertical, our Dapibus™ microbial cell line continues to gain traction in several areas, including the cultured meat indus...